在临床试验中使用白癜风可见性量表:结构效度、可解释性、信度与可接受性
基于HI-Light白癜风试验的图像与结局数据,评估白癜风可见性量表(VNS)的心理测量学特性。VNS与参与者报告的整体治疗成功相关(κ=0·41,若VNS成功定义为≥4;κ=0·71,若定义为≥3),且高于临床医生报告的复色百分比(κ=0·17)。75%的试验参与者认为VNS为3分(部分应答)即治疗成功;重测信度良好(κ=0·69,95%CI 0·63-0·74)。
要点
- VNS与参与者报告的整体成功相关,κ=0·41(VNS≥4)或κ=0·71(VNS≥3)。
- VNS与参与者报告成功的关联高于临床医生报告的复色百分比(κ=0·41 vs 0·17)。
- 75%的试验参与者认为VNS为3分(部分应答)即治疗成功。
核心结论
- 试验参与者对白癜风的评估可能与盲法评估者不同。
- VNS评分3分可能比之前认为的更受接受白癜风治疗者重视。
研究设计与样本
- 使用HI-Light白癜风试验的治疗前后图像及结局数据,比较试验参与者与临床医生及非试验参与者的白癜风患者(患者与公众参与小组)对图像的评估。
- 通过假设检验评估VNS的心理测量学特性,使用κ统计量评估结局之间的一致性。
- 三个焦点小组和两个在线讨论组提供白癜风患者使用VNS的见解。
主要发现
- VNS与参与者报告的整体治疗成功呈正相关的假设在试验参与者中得到支持(κ=0·41,若VNS成功定义为≥4;κ=0·71,若定义为≥3),但在盲法患者与公众参与小组中未得到支持(κ=0·28)。
- 如假设,VNS与参与者报告的整体成功的关联(κ=0·41)高于临床医生报告的复色百分比(κ=0·17)。
- 75%的试验参与者认为VNS为3分(部分应答)是治疗成功。
- 重测信度良好:κ=0·69(95%置信区间0·63-0·74)。
- 年龄和皮肤光型不影响VNS评分的解释。
关键数值与推荐
- VNS与参与者报告的整体成功:κ=0·41(VNS成功定义为≥4)或κ=0·71(定义为≥3)。
- 盲法患者与公众参与小组中VNS与参与者报告的整体成功:κ=0·28。
- 临床医生报告的复色百分比与参与者报告的整体成功:κ=0·17。
- 重测信度:κ=0·69(95%置信区间0·63-0·74)。
临床怎么用
- VNS可作为患者报告结局测量工具,用于评估单个白癜风斑块复色的美容可接受性。
- VNS评分3分或以上可能被患者视为治疗成功。
- 应报告VNS所有五个等级以保持透明度,有助于解释试验结果并促进系统评价中的Meta分析。
- 建议尽可能对试验参与者实施盲法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Validated outcome measures are needed for vitiligo trials. OBJECTIVES: To assess construct validity, interpretability, reliability and acceptability of the Vitiligo Noticeability Scale (VNS). METHODS: We used images of vitiligo before and after treatment, plus outcome data, from the HI-Light Vitiligo trial. We compared outcome assessments made by trial participants with assessments of images by clinicians and people with vitiligo who were not trial participants [Patient and Public Involvement (PPI) panel]. Hypothesis testing assessed psychometric properties of the VNS, with κ statistics to assess agreement between outcomes. Three focus groups and two online discussion groups provided insight into the use of VNS by people with vitiligo. RESULTS: Our hypothesis of a positive association between VNS and participant-reported global treatment success was supported for trial participants (κ = 0·41 if VNS success was defined as ≥ 4; κ = 0·71 if VNS success was defined as ≥ 3), but not for the blinded PPI panel (κ = 0·28). As hypothesized, the association with participant-reported global success was higher for VNS (κ = 0·41) than for clinician-reported percentage repigmentation (κ = 0·17). Seventy-five per cent of trial participants valued a VNS of 3 (partial response) as a treatment success. Test-retest reliability was good: κ = 0·69 (95% confidence interval 0·63-0·74). Age and skin phototype did not influence interpretation of the VNS scores. To people with vitiligo, the VNS is an acceptable and meaningful patient-reported outcome measure. CONCLUSIONS: Trial participants may assess their vitiligo differently compared with blinded assessors. A VNS score of 3 may be more highly valued by people undergoing vitiligo treatment than was previously thought. What is already known about this topic? Vitiligo is a common condition, and can have a considerable psychological impact. A Vitiligo Core Outcome Set is being developed, to enable the results of vitiligo trials to be compared and combined more easily. The Vitiligo Noticeability Scale (VNS) is a patient-reported outcome measure (PROM) developed in partnership with people with vitiligo; initial validation studies have been promising. What does this study add? The VNS shows good construct validity, reliability and acceptability; it can be used in all ages and skin phototypes. All five levels of the VNS scale should be reported for transparency, to aid interpretation of trial findings, and to facilitate meta-analysis in systematic reviews. VNS assessments made by trial participants and independent observers are likely to be qualitatively different, making blinded assessment of VNS by independent observers difficult to interpret. Blinding of participants to trial interventions is recommended whenever possible. What are the clinical implications of the work? The VNS can be used as a PROM to assess the cosmetic acceptability of repigmentation at individual patches of vitiligo. A VNS score of 3 or more is likely to be valued by patients as a treatment success.
引用
- Batchelor JM, Gran S, Leighton P, et al. Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability. Br J Dermatol. 2022. PMID: 35596714. doi:10.1111/bjd.21671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。